RxDoctor Payments DataLook up a doctor →

Mitchell Cagle, NP

Family · Northport, ALNPI 1306396676

Payments from drug & device makers

$13,372in general payments, 2019–2025

Across 757 payments — averaging $17.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • AstraZeneca$982
  • Pfizer$911
  • Lilly USA, LLC$900
  • GSK$877
  • plus $7K from 36 others

What the payments were for

  • Food & beverage$13,27299%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,372 in reported general payments places this provider in the 95th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$71,075
Medicare patients
288
Services billed
2,217

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide136$191,372
MounjaroTirzepatide73$113,272
JardianceEmpagliflozin30$42,778
Synjardy XrEmpagliflozin/Metformin Hcl34$31,391
Janumet XrSitagliptin Phos/Metformin Hcl18$27,230
EliquisApixaban29$25,985
JanuviaSitagliptin Phosphate26$25,480
TrulicityDulaglutide19$24,645
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$22,195
Xigduo XrDapaglifloz Propaned/Metformin20$20,983
RybelsusSemaglutide12$20,901
XareltoRivaroxaban13$14,440
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$11,565
MyrbetriqMirabegron14$11,161
Pitavastatin Calcium12$6,917

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,202$212,273148 claims
Lilly USA, LLCMounjaro, Trulicity$900$137,91692 claims
Boehringer IngelheimJardiance, Synjardy Xr$721$74,16964 claims
MerckJanumet Xr, Januvia$277$52,71044 claims
PfizerEliquis$911$25,98529 claims
GSKTrelegy Ellipta$877$22,19517 claims
Johnson & JohnsonXarelto$495$14,44013 claims
Astellas Pharma US IncMyrbetriq$247$11,16114 claims
Kowa Pharmaceuticals America, Inc.Livalo$94$6,25012 claims
AbbVieSynthroid$1,722$1,73816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,415 family providers in Alabama.

Other family in Northport

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →